💊
Raloxifene Teva
raloxifene
Osteoporose, postmenopauzaal
✅ Geautoriseerd
Algemeen
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
⚠️ Patiëntveiligheid
No
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/raloxifene-teva